MEDP
Medpace Holdings, Inc.
+2.68 (+0.43%)619.12USD66.9K成交股數17.3B市值36.3本益比(近四季)6.2股價營收比+17.2%營收年增(近四季)2026-10-19下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 707M+17% | 707M+27% | 708M+33% | 660M+25% | 603M+18% | 559M+12% | 533M+8% | 528M+15% | 511M | 498M | 492M | 461M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | – | – | – | – | – | – | – | – | – | – | – | – |
| 銷售管理費用 | 48.1M | 47.9M | 44.9M | 48.1M | 46.7M | 57.9M | 49.2M | 41.5M | 44.1M | 42.5M | 41.4M | 39.4M |
| 營業利益 | 147M+16% | 142M+25% | 153M+37% | 142M+35% | 126M+21% | 114M+30% | 112M+32% | 105M+34% | 104M | 87.3M | 84.9M | 78.4M |
| 營業利益率 | 20.8% | 20.0% | 21.6% | 21.5% | 20.9% | 20.3% | 21.1% | 19.9% | 20.4% | 17.5% | 17.2% | 17.0% |
| 稅後淨利 | 121M+34% | 124M+8% | 135M+40% | 111M+26% | 90.3M-12% | 115M+46% | 96.4M+37% | 88.4M+45% | 103M | 78.3M | 70.6M | 61.1M |
| 淨利率 | 17.2% | 17.5% | 19.1% | 16.8% | 15.0% | 20.5% | 18.1% | 16.7% | 20.1% | 15.7% | 14.3% | 13.3% |
| 稀釋 EPS | 4.25+37% | 4.28+17% | 4.65+54% | 3.86+40% | 3.10-3% | 3.67+49% | 3.01+36% | 2.75+42% | 3.20 | 2.46 | 2.22 | 1.93 |
| 稀釋股數 | 28.6M | 29.0M | 29.5M | 28.8M | 29.1M | 31.2M | 32.1M | 32.1M | 32.0M | 31.8M | 31.8M | 31.6M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 503M | 653M | 497M | 285M | 46.3M | 441M | 657M | 511M | 407M | 245M | 95.2M | 39.1M |
| 應收帳款 | 442M | 395M | 402M | 373M | 378M | 298M | 311M | 301M | 279M | 298M | 293M | 275M |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 2.1B | 2.1B | 2.0B | 1.8B | 1.6B | 1.9B | 2.1B | 1.9B | 1.8B | 1.7B | 1.5B | 1.4B |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 1.6B | 1.5B | 1.5B | 1.5B | 1.4B | 1.3B | 1.2B | 1.2B | 1.1B | 1.1B | 1.0B | 1.0B |
| 股東權益 | 434M | 598M | 459M | 294M | 172M | 594M | 881M | 764M | 672M | 559M | 471M | 391M |
| 負債比 | 78.9% | 71.9% | 76.8% | 83.2% | 89.0% | 68.7% | 57.7% | 60.2% | 62.6% | 66.3% | 68.3% | 72.2% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 152M+21% | – | – | – | 126M | – | – | 153M | – | – | – |
| 資本支出 | – | 6.8M | – | – | – | 10.0M | – | – | 5.5M | – | – | – |
| 自由現金流 | – | 145M+25% | – | – | – | 116M | – | – | 147M | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | 0.00 | – | – | – | 372M | – | – | 0.00 | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 20.5% | – | – | – | 20.7% | – | – | 28.8% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 2.5B
| Reportable | 2.5B | 100.0% | +20.0% |
|---|
產品／服務2025 年度 · 2.5B
| Oncology | 748M | 29.5% | +14.8% |
|---|---|---|---|
| Metabolic | 745M | 29.4% | +62.8% |
| 其他 | 409M | 16.1% | -5.3% |
| Central Nervous System | 255M | 10.1% | +40.0% |
| Cardiology | 239M | 9.5% | +3.9% |
| Antiviral And Anti Infective | 135M | 5.3% | -13.8% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 2.5B | +20.0% | 451M | 17.8% | 15.28 | 682M |
| FY2024 | 2.1B | +11.8% | 404M | 19.2% | 12.63 | 572M |
| FY2023 | 1.9B | +29.2% | 283M | 15.0% | 8.88 | 397M |
| FY2022 | 1.5B | +27.8% | 245M | 16.8% | 7.28 | 351M |
| FY2021 | 1.1B | +23.4% | 182M | 15.9% | 4.81 | 235M |
| FY2020 | 926M | +7.5% | 145M | 15.7% | 3.84 | 227M |
| FY2019 | 861M | +22.2% | 100M | 11.7% | 2.67 | 184M |
| FY2018 | 705M | – | 73.2M | 10.4% | 1.97 | 141M |